Beyond Extrapolation: What This Study Asked
Recurrent vulvar and vaginal carcinoma is rare, aggressive, and often difficult to treat once it returns after standard therapy. Because these cancers are uncommon, many treatment decisions are based on data borrowed from more common gynecologic cancers rather than on large dedicated trials. This study examined whether immune checkpoint inhibitors, a class of immunotherapy drugs that help the immune system recognize and attack cancer cells, offer meaningful benefit in recurrent vulvovaginal carcinoma (VVC).
The investigators looked at patients treated at a single tertiary care center over nearly a decade and focused on several key outcomes: response to treatment, how long responses lasted, how long patients lived without the cancer worsening, overall survival, and treatment-related toxicity. The goal was to better understand the real-world performance of immunotherapy in a very small but clinically important patient population.
Why Immunotherapy Matters in Vulvovaginal Cancer
Immune checkpoint inhibitors, such as pembrolizumab, work by blocking signals that tumors use to turn off immune cells. In gynecologic oncology, these agents have changed care in several cancers, especially when tumors express PD-L1 or show features suggesting immune sensitivity. For vulvar and vaginal cancers, however, evidence has been limited because these cancers are rare and often grouped together in studies.
That rarity creates a practical challenge. Clinicians may know that a drug is active in cervical or endometrial cancer, but it is less clear whether the same benefit applies to vulvar or vaginal cancer. This study helps fill that gap by reporting actual outcomes rather than relying only on extrapolation from other diseases.
Study Design and Patient Population
This retrospective cohort study included 21 patients with recurrent vulvar or vaginal carcinoma who received immune checkpoint inhibitor therapy between August 2016 and September 2025. The median age was 73.0 years, with an interquartile range of 62.4 to 77.9 years, reflecting a mostly older population typical of this disease.
Seventeen patients were evaluable for tumor response. Most patients had PD-L1-positive tumors, defined as a combined positive score of at least 1, in 85.7% of cases. Pembrolizumab was the most commonly used immunotherapy agent, given to 76.2% of patients. The majority received immunotherapy alone rather than in combination with other drugs, and the median number of treatment cycles was 4.
The researchers used RECIST 1.1 criteria, a standard method for measuring changes in tumor size on imaging, to determine how well treatment was working.
Key Efficacy Findings
The objective response rate, or ORR, was 29.4%, meaning that about 3 in 10 evaluable patients had a measurable tumor shrinkage. Five patients achieved a response. Among responders, the median duration of response was 14.0 months, showing that when benefit occurred, it could last a substantial time for some patients.
However, overall disease control remained limited for many patients. The median progression-free survival, or PFS, was 3.0 months, meaning that half of the patients experienced disease progression or death within about three months of starting immunotherapy. The median overall survival, or OS, was 4.6 months.
When comparing treatment approaches, median PFS was 3.1 months in patients receiving combination therapy and 2.5 months in those receiving monotherapy. This difference was not statistically significant. In practical terms, the study did not show a clear survival advantage for combination treatment in this small cohort.
What the Results Mean in Practice
The most encouraging finding was that a subset of patients experienced durable benefit. A response lasting a median of 14 months suggests that immunotherapy can produce meaningful and sustained tumor control in selected cases, even though the average outcomes were modest.
This pattern is familiar in immuno-oncology: many patients do not respond, but those who do may experience long-lasting disease control. For rare cancers like recurrent vulvar and vaginal carcinoma, even a small but durable response rate can matter, especially when treatment options are limited and the disease is difficult to manage after recurrence.
The high rate of PD-L1 positivity in this study may help explain why some patients benefited. Still, PD-L1 is not a perfect biomarker, and not all PD-L1-positive tumors respond. Other factors, such as tumor mutation burden, immune cell infiltration, prior treatment history, and overall performance status, may also influence response.
Safety and Tolerability
Immune-related adverse events occurred in 38.1% of patients. These side effects happen when immunotherapy overstimulates the immune system, which can lead to inflammation in organs such as the skin, gut, liver, lungs, thyroid, or other endocrine organs. In this study, 19.0% of patients experienced grade 3 or higher events, which are considered severe.
This toxicity profile is consistent with known risks of checkpoint inhibitors. While many side effects can be managed with prompt recognition and corticosteroids or treatment interruption, severe immune-related events may limit ongoing therapy. Treatment discontinuation most often occurred because of disease progression rather than toxicity, which suggests that lack of efficacy remained the main clinical challenge.
Clinical Takeaways
For clinicians, this study reinforces several important points. First, immunotherapy should not be viewed as universally effective in recurrent vulvovaginal carcinoma, but it can be valuable for a select group of patients. Second, responses may be durable when they occur, making immunotherapy worth considering even in heavily pretreated disease. Third, toxicities are manageable in many cases but require close monitoring.
Pembrolizumab appears to be the most commonly used checkpoint inhibitor in this setting, likely because of broader gynecologic oncology experience and access to biomarker-driven indications. Nevertheless, the study does not prove that one immunotherapy approach is superior to another, nor does it establish an optimal sequence or combination strategy.
Limitations of the Study
This was a retrospective, single-center study with a small sample size, which limits the strength of the conclusions. Recurrent vulvar and vaginal cancers are rare, so even the collection of 21 patients over many years is clinically meaningful, but still too small to make definitive treatment recommendations.
There were also differences in prior therapies, tumor characteristics, and treatment regimens, which can influence outcomes. Not every patient was evaluable for response, and real-world retrospective analyses are vulnerable to missing data and selection bias. In addition, the combined reporting of vulvar and vaginal carcinomas reflects practical clinical reality but may obscure differences between the two disease types.
Where the Field Goes Next
Future research should focus on larger multicenter collaborations, biomarker refinement, and combination strategies. Potential directions include pairing checkpoint inhibitors with chemotherapy, anti-angiogenic therapy, radiation, or other immune-modulating agents. Better molecular characterization may also help identify which patients are most likely to benefit.
Because these cancers are rare, collaborative registries and pooled analyses may be the best way to move the field forward. Randomized trials are difficult but important, and real-world data like this study provide an essential foundation for designing them.
Bottom Line
Immune checkpoint inhibitors showed modest overall activity in recurrent vulvar and vaginal carcinoma, but a small subset of patients experienced durable responses. The study suggests that immunotherapy may offer meaningful benefit for select patients, especially those with biomarker-positive disease, even though average survival outcomes remain limited. In a rare cancer with few effective options, that signal of durable benefit is clinically important.
